Kangsheng Xuyuan introduced several more PacBio (PACB. US) and MGI (688114) high-throughput sequencers to create a new highland for scientific research multi-omics centralized services
DATE:  Feb 14 2025

Recently, Kangsheng Xuyuan Biotechnology (Wuhan) Co., Ltd., a holding subsidiary of Kangsheng Global (09960), a large high-end medical specialty special inspection group in China, announced that Kangsheng Xuyuan has introduced two more PacBio Revio third-generation sequencing systems and one DNBSEQ-T7 second-generation sequencer manufactured by BGI.

After this introduction, Kangsheng Xuyuan will have 3 PacBio Revios, of which 2 Revio systems are positioned to provide long-read sequencing services for the domestic market, and 1 Revio system is positioned to provide full-process long-read sequencing services for overseas markets (from sample customs clearance, extraction and library construction to data delivery).

At the same time, Kangsheng Sequin has comprehensively upgraded PacBio's latest SPRQ reagents, increasing the output of a single cell by up to ~49%, and will be in the forefront of PacBio service providers in China in terms of total delivery capacity and throughput of PacBio sequencing. Each Revio instrument is capable of completing up to 2,500 20-fold human whole-genome sequencing per year at a cost of less than $500 per human genome ($750 per genome covering 30 times the human genome) for the same Revio run time.

Comparison of SPRQ reagent upgrade throughput and data output

In terms of qualifications, Kangshengxu originated from the first batch of PacBio official certified service providers in the Asia-Pacific region in December 2023:

In terms of qualifications, Kangshengxu originated from the first batch of PacBio official certified service providers in the Asia-Pacific region in December 2023

In terms of next-generation sequencing and multi-omics services, on the basis of the introduction of a complete set of BGI DCS Lab last year and the qualification of the official certified service provider of BGI DCS Lab, Kangsheng will own and operate 2 DNBSEQ-T7, 1 Stereo-seq platform, 1 BGI Stereo-seq platform, 1 BGI Nanopore WT02, and multiple single-cell DNBelab C4 instruments, as well as 8 second-generation sequencing and single-cell sequencing platforms of other brands.

After the introduction of this time, Kangsheng Xuyuan has built a large-scale scientific research multi-omics service center based in Central China, radiating the national and overseas markets, and enabling special inspections of specialists. The service center has a comprehensive platform and complete service qualifications, and has rich project experience; Its service areas include genomics and transcriptomics services based on third-generation long-read sequencing and second-generation short-read sequencing, single-cell omics and spatiotemporal omics services, bioanalysis and gene cloud services. The service center qualification is complete, and the company has obtained the qualification of PacBio and MGI official service provider, and has also obtained the ISO9001 quality management system certification

In terms of service experience, since its establishment, Kangsheng Xuyuan has served more than 5,000 customers, more than 500 companies, more than 100 tertiary hospitals at home and abroad, and successfully delivered 5,000+ projects; In terms of business layout, Kangsheng Xuyuan Service Center has a rich long-term layout and practice in multi-omics research of population cohorts, multi-omics LDT product development in medical specialties such as hematology/neurology, pretreatment of medical difficult multi-omics samples and full-length products of microbial diversity, so as to provide global customers with "one-stop multi-omics scientific research services from sample to data".

At present, the downward trend of the cost of global scientific research multi-omics tools has surpassed Moore's law, and the centralization and localization of scientific research services have become the internal demand of the scientific research multi-omics market. After the introduction of this time, the rich configuration of Kangsheng Xuyuan Multi-omics Service Center will be able to meet the needs of national and overseas customers for different types and levels of services such as next-generation sequencing and NGS sequencing, single-cell and spatiotemporal omics, etc., truly reduce the potential secondary outsourcing cost of multi-omics services for customers, improve the quality of comprehensive services, and better meet the needs of customers' scientific research projects, so that Kangsheng multi-omics scientific research services can truly benefit more basic and medical research workers.

Follow Yicai Global on

star50stocks

Ticker Name

Percentage Change

Inclusion Date